162. Pemphigoid
70 clinical trials,   117 drugs   (DrugBank: 46 drugs),   30 drug target genes,   128 drug target pathways

Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04563923
(ClinicalTrials.gov)
October 10, 202017/9/2020Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal AntibodyTreatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal AntibodyBullous PemphigoidDrug: Avdoralimab (IPH5401);Other: ControlCentre Hospitalier Universitaire de NiceNULLRecruiting18 YearsN/AAll40Phase 2France
2EUCTR2020-002912-34-FR
(EUCTR)
11/08/202022/06/2020Treatment of bullous pemphigoid with avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibodyTreatment of bullous pemphigoid with avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibody - PB Auto Immune bullous Diseases;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Product Name: avdoralimab
Product Code: IPH5401
INN or Proposed INN: avdoralimab
Other descriptive name: NNC0215-0384
CHU NICENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2France